Seo Hyo-seok, a specialist in Korean traditional medicine, is visiting the United States for a week to promote his unique technique for the treatment of chronic lung conditions like asthma, atopic dermatitis, pulmonary fibrosis and chronic obstructive pulmonary disease (COPD). The doctor is the head of the Pyunkang Korean…
News
Specialty pharmaceutical company Pacific Therapeutics Ltd., known for their strategy on reformulating and improving pre existing FDA-approved drugs, has several leading pipeline products and ongoing research programs targeted at $1 billion dollar markets for erectile dysfunction and pulmonary fibrosis. Recently,…
Emerging product development and commercialization company Allied Minds has just launched a divisional biopharmaceutical company that will specialize in the utilization of a protein called, RHAMM or Receptor for Hyaluronan Mediated Motility, for the creation of products indicated to enhance the body’s natural reparative mechanisms. The company, Novare Pharmaceuticals, is aiming…
Although multi walled carbon nanotubes (CNTs) are all the rage in product development, finding applications in sporting goods, electronic devices, and many other products, they pose a potential health hazard similar to asbestos. However, Dr. James Bonner, a professor at North Carolina State University, found a way to reduce…
A case study of pulmonary fibrosis (PF) in association with autoimmune diseases, entitled “A case of pulmonary fibrosis associated with rheumatoid arthritis, scleroderma sine scleroderma and ANCA associated vasculitis” was published in SpringerPlus by Dr. Amritpal Singh Anand from Lakeland Rheumatology and colleagues in Michigan describing a rare…
A new study offering insights into pulmonary fibrosis, entitled “Secreted frizzled related proteins inhibit fibrosis in vitro but appear redundant in vivo” was published in Fibrogenesis &Tissue Repair by Dr. Rik JU Lories’ research group at University Hospitals Leuven in Belgium. In this new research, the authors investigated…
During the European Respiratory Society International Congress (ERS) 2014, held in Munich, Germany last month, a pre-specified subgroup analysis from the two replicate Phase III INPULSIS™ trials revealed that treatment with nintedanib retarded the decline in lung function in patients with idiopathic pulmonary fibrosis (IPF). The study’s findings were…
For the first time ever, a new European Patient Charter for patients who suffer from idiopathic pulmonary fibrosis (IPF) was developed by a group of advocates and presented to the European Parliament on September 30, during IPF World Week 2014. Biotechnology company InterMune, which is dedicated to research, development,…
Drug development company Promedior Inc. recently announced the results of its Phase 1B clinical trial of PRM-15 for treating Idiopathic Pulmonary Fibrosis (IPF). Their findings show that structural and functional imaging of IPF patients correlate with data obtained from standard pulmonary tests. The new data could lead to further development of the therapy as an…
Germany-based multinational pharmaceutical company Boehringer Ingelheim has launched a new mobile app and web page self-test as part of its efforts to raise awareness of Idiopathic pulmonary fibrosis (IPF), a chronic, progressive, severely debilitating, and ultimately lethal lung disease for which there are no FDA-approved treatment options in the U.S. Although…
